Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ravulizumab (Primary) ; Eculizumab
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 301
  • Sponsors Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 01 Jan 2024 Results of post-hoc analysis assessing clinical outcomes and PROs from 246 complement inhibitor-naive patients with PNH , published in the Annals of Hematology.
    • 12 Dec 2023 Results reporting ravulizumab treatment outcomes for up to 6 years in patients with PNH from study 301 and comparing survival with untreated patients of the International PNH Registry (NCT01374360), presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 14 Jun 2023 This trial has been Completed in Poland, According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top